Abstract
Drug approval is the goal of the long process of drug development. Once preclinical and clinical trial data have been collected, a New Drug Application must be submitted to the regulatory authority for approval. Although the requirements for this submission have similarities around the world, until now, the applications have been different. Regulatory authorities working under the umbrella of the International Conference on Harmonisation are hoping that the development of the Common Technical Document will soon harmonize the application procedure, and make this process simpler for applicants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
FURTHER INFORMATION
Center for Drug Evaluation and Research
Center for Drug Evaluation and Research Handbook
Center for Drug Evaluation and Research Learn
European Commission of the European Union
European Federation of Pharmaceutical Industries and Associations
International Conference on Harmonisation
International Federation of Pharmaceutical Manufacturers Association
Rights and permissions
About this article
Cite this article
Molzon, J. The Common Technical Document: the changing face of the New Drug Application. Nat Rev Drug Discov 2, 71–74 (2003). https://doi.org/10.1038/nrd990
Issue Date:
DOI: https://doi.org/10.1038/nrd990
This article is cited by
-
Awareness about FDA announcement on voluntary recall of ranitidine among physicians and pharmacists in and around Chennai, India: a cross-sectional study
Future Journal of Pharmaceutical Sciences (2021)
-
The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health
Clinical Pharmacology & Therapeutics (2011)
-
Antimalarial drug discovery: efficacy models for compound screening
Nature Reviews Drug Discovery (2004)
-
Virtual drug discovery and development for neglected diseases through public–private partnerships
Nature Reviews Drug Discovery (2003)